Martin de Borst, M.D., Ph.D., is consultant nephrologist at the University Medical Center Groningen and adjunct professor of medicine at the University of Groningen. He was trained at the University of Groningen, the Netherlands, and received post-doctoral training at the Mario Negri Institute for Pharmacological Research in Bergamo, Italy from 2006-2007.

Prof. De Borst’s research focuses on the interaction between chronic kidney disease and cardiovascular complications. His main scientific aim is to identify targetable factors and innovative treatments to prevent progressive kidney function loss and the development of cardiovascular disease. So far, he has published >220 peer-reviewed articles that have been cited >6500 times. His work is embedded in several national and international research consortia, and is supported by national and European funding. He supervises a team of twelve PhD students, three post-docs, two research analysts and many students. He is the co-founder of NOVO, a national platform that facilitates clinical trials and large cohort studies in the Netherlands. He is (co-)Principal Investigator of several multicenter clinical trials, including the K+ in CKD trial (clinicaltrials.gov NCT03253172) and the EFFECT-KTx study (NCT03769441). In 2020, he received the Stanley Shaldon award for young investigators from the European Renal Association (ERA-EDTA).

Prof. De Borst is Associate Editor of Nephrology Dialysis Transplantation, the flagship scientific journal of the ERA-EDTA. He is also Part President of the Young Nephrologists’ Platform, an ERA-EDTA committee dedicated to promoting the development of young kidney specialists in Europe.